Published in Health Business Week, June 29th, 2007
Study 1: Data detailed in "Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment" have been presented. According to a study from the United States, "The World Federation of Hemophilia estimates that of the 400,000 individuals worldwide with hemophilia, 300,000 receive either no, or very sporadic, treatment. Thus, considerable innovation will be required to provide cost-effective therapies/cures for all affected individuals."
"The high cost of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.